One-Compound-Multi-Target: Combination Prospect of Natural Compounds with Thrombolytic Therapy in Acute Ischemic Stroke

Abstract: Tissue plasminogen activator (t-PA) is the only FDA-approved drug for acute ischemic stroke treatment, but its clinical use is limited due to the narrow therapeutic time window and severe adverse effects, including hemorrhagic transformation (HT) and neurotoxicity. One of the potential res...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Han-Sen, Qi, Su-Hua, Shen, Jian-Gang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Bentham Science Publishers 2017
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5327453/
https://www.ncbi.nlm.nih.gov/pubmed/27334020
http://dx.doi.org/10.2174/1570159X14666160620102055

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5327453/
https://www.ncbi.nlm.nih.gov/pubmed/27334020
http://dx.doi.org/10.2174/1570159X14666160620102055

Ejemplares similares